Back
Open Access

Bioactive adrenomedullin as a predictor of clinical outcomes in cardiac transthyretin amyloidosis

Session: Beating the odds: advances in cardiac amyloidosis treatment
Topic: Clinical
Speaker: Mr M. Mueller (Berlin, DE)
Event: Heart Failure 2025

Congress Presentation

Add to my library

Like

About the speaker

Mr Maximilian Mueller

Deutsches Herzzentrum der Charite, Berlin (Germany)
0 follower

6 more presentations in this session

Cause of death in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): findings from the ATTRibute-CM study

Speaker: Doctor L. Obici (Pavia, IT)

Access
Abstract
Like
Thumbnail

Effect of acoramidis on functional capacity and quality of life in patients with variant ATTR-CM: results from ATTRibute-CM

Speaker: Professor M. Fontana (London, GB)

Access
Abstract
Like
Thumbnail

Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM

Speaker: Professor M. Fontana (London, GB)

Access
Abstract
Like
Thumbnail

Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRibute-CM trial

Speaker: Assistant Professor K. Alexander (Palo Alto, US)

Access
Abstract
Like
Thumbnail

Neurohormonal therapies at baseline and follow-up and survival in patients with wild-type transthyretin cardiac amyloidosis

Speaker: Doctor A. Aimo (Pisa, IT)

Access
Abstract
Like
Thumbnail

Access the full session

Beating the odds: advances in cardiac amyloidosis treatment

Speakers: Mr M. Mueller, Doctor L. Obici, Professor M. Fontana, Professor M. Fontana, Assistant Professor K. Alexander...
Access
Like
Thumbnail

About the event

Image

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novartis Explore sponsored resources
logo Novo Nordisk Explore sponsored resources